Clinical trials: sponsored by Amgen
Obesity
Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity
The primary objective of this study is to assess the safety and tolerability of AMG 786 as single or multiple doses in healthy and obese participants.
- Trial name
- NCT05406115
- Testing
- AMG 786
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Amgen
Atherosclerotic Cardiovascular Disease
A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)
The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of ASCVD as defined by their medical history and is 2-fold: Evaluate the distribution of Lp(a) value…
- Trial name
- NCT05378529
- Testing
- Lp(a) Screening
- Where
- 735 sites in United States, Argentina and 34 more
- Volunteers
- 39,480 people
- Sponsor
- Amgen
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.
- Trial name
- NCT04185883
- Testing
- Sotorasib, Trametinib, RMC-4630
- Where
- 90 sites in United States, Australia and 11 more
- Volunteers
- 610 people
- Sponsor
- Amgen
Chronic Uncontrolled Gout, Gout
Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate
The purpose of this study is to assess the safety, tolerability and efficiency of pegloticase administered with a shorter infusion duration in participants with uncontrolled gout receiving methotrexate.
- Conditions
- Chronic Uncontrolled Gout, Gout, Uncontrolled Gout
- Trial name
- NCT04511702
- Testing
- Pegloticase with MTX
- Where
- 39 sites in United States
- Volunteers
- 191 people
- Sponsor
- Amgen
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of prostate specific membrane antigen half-life extended bispecific T-cell engager acapatamab in subjects with metastatic castration-resistant…
- Trial name
- NCT03792841
- Testing
- acapatamab, Pembrolizumab, Etanercept
- Where
- 30 sites in United States, Australia and 8 more
- Volunteers
- 212 people
- Sponsor
- Amgen
Small Cell Lung Cancer
A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC
A study to evaluate the safety and tolerability of AMG 119 in adult subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC) and determine the appropriate cell dose.
- Trial name
- NCT03392064
- Testing
- AMG 119
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Amgen
Ulcerative Colitis
Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis
The primary objective of this study is to evaluate the long-term safety and tolerability of efavaleukin alfa in participants with moderate to severe ulcerative colitis (UC).
- Trial name
- NCT05672199
- Testing
- Efavaleukin alfa
- Where
- 25 sites in United States, Argentina and 11 more
- Volunteers
- 25 people
- Sponsor
- Amgen
MUC17-positive Solid Tumors
Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers
To evaluate the safety and tolerability of AMG 199 in adult subjects and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
- Trial name
- NCT04117958
- Testing
- AMG 199
- Where
- 21 sites in United States, Austria and 7 more
- Volunteers
- 58 people
- Sponsor
- Amgen
Non-squamous Non-small Cell Lung Cancer, Epithelial Ovarian Cancer
A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications
The primary objectives of this study are to evaluate the safety and tolerability of AMG 794 in adult participants and to determine the optimal biological active dose (OBD), at or below the maximum tolerated dose (MTD) with MTD 1…
- Conditions
- Non-squamous Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, Claudin 6-positive Advanced/Metastatic Malignant Solid Tumors
- Trial name
- NCT05317078
- Testing
- AMG 794
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 3 people
- Sponsor
- Amgen
Overweight, Obesity
A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity
The primary objective of this study is to assess the pharmacokinetics (PK) of AMG 133 after multiple subcutaneous (SC) administrations in participants with overweight or obesity using various dose regimens.
- Trial name
- NCT06976372
- Testing
- AMG 133
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Amgen
Relapsed/Refractory Multiple Myeloma
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
The primary purpose of the phase 1 part of the study is to evaluate safety and tolerability of AMG 701 monotherapy to identify the RP2D for AMG 701 monotherapy followed by a dose-confirmation part to gather further safety data…
- Trial name
- NCT03287908
- Testing
- AMG 701, Pomalidomide, Dexamethasone
- Where
- 34 sites in United States, Australia and 4 more
- Volunteers
- 174 people
- Sponsor
- Amgen
Cardiovascular Disease, Myocardial Infarction
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial…
- Conditions
- Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
- Trial name
- EVOLVE-MI (NCT05284747)
- Testing
- Evolocumab, Routine Lipid Management
- Where
- 120 sites in United States, Brazil and 1 more
- Volunteers
- 6,019 people
- Sponsor
- Amgen
Giant Cell Tumor of Bone
Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
The study aims to evaluate the efficacy of XGEVA® in Chinese participants with giant cell tumor of bone (GCTB).
- Trial name
- NCT04586660
- Testing
- XGEVA®
- Where
- 10 sites in China, Taiwan
- Volunteers
- 36 people
- Sponsor
- Amgen
Small Cell Lung Cancer
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
The main purpose of this study is to evaluate the safety, tolerability, and recommended phase 2 target dose of tarlatamab in combination with AMG 404.
- Trial name
- NCT04885998
- Testing
- Tarlatamab, AMG 404
- Where
- 17 sites in United States, Austria and 4 more
- Volunteers
- 23 people
- Sponsor
- Amgen
Migraine Headache
A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache
Study 20170703 is a phase 4, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of erenumab against placebo in participants with chronic migraine (CM) who have a history of at…
- Trial name
- NCT03971071
- Testing
- Erenumab 70 mg, Erenumab 140 mg
- Where
- 94 sites in United States, Australia and 10 more
- Volunteers
- 620 people
- Sponsor
- Amgen
Neuroendocrine Prostate Cancer
A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer
To evaluate the safety and tolerability of Tarlatamab and will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
- Trial name
- DeLLpro-300 (NCT04702737)
- Testing
- Tarlatamab
- Where
- 21 sites in United States, Australia and 7 more
- Volunteers
- 41 people
- Sponsor
- Amgen
Relapsed and/or Refractory Multiple Myeloma
Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma
To confirm the maximum tolerated dose (MTD) from the BI 836909 trial of 400 mcg/d, given as 28-day continuous intravenous infusion in patients with relapsed and/or refractory multiple myeloma, to test the 600 mcg/d dose, given as…
- Trial name
- AMG420 (NCT03836053)
- Testing
- AMG 420
- Where
- 10 sites in United States, Australia and 3 more
- Volunteers
- 23 people
- Sponsor
- Amgen
Neovascular (Wet) Age-related Macular Degeneration (AMD)
A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]
The purpose of this study is to compare the efficacy and safety of ABP 938 versus Aflibercept (Eylea®) in the treatment of neovascular age-related macular degeneration.
- Trial name
- NCT04270747
- Testing
- ABP 938, Aflibercept
- Where
- 118 sites in United States, Canada and 16 more
- Volunteers
- 576 people
- Sponsor
- Amgen
Thyroid Eye Disease
Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients
The main objective of this study is to assess the number of participants with proptosis response as of last intravenous infusion of teprotumumab.
- Trial name
- NCT07085117
- Testing
- Teprotumumab
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Amgen
Psoriasis
Post-Marketing Surveillance Study of OTEZLA
To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis arthropathica 1.
- Trial name
- NCT03284879
- Where
- Japan
- Volunteers
- 1,086 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.